Researchers suggest that access to treatment and socioeconomic resources can influence glycemic control and disparities in the management of patients with Type 1 diabetes.

Proposed premium increases in the ACA Marketplace for 2026 surge due to rising healthcare costs, specialty drug prices and subsidy uncertainties, according to a recent KFF analysis.

A new study shows Medicare can pay plans more fairly for caring for people from different racial and ethnic backgrounds without breaking the system.

Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Humana enhances value-based care for Medicare Advantage members with new partnerships, addressing rising musculoskeletal condition costs and improving patient outcomes.

The approval letter to Pfizer and its BioNTech mentions the companies' commitment to conduct four postmarketing studies of ...

EP: 5. Bridging the Gap: Ways to Overcome Barriers of Access to Anti-CD38 Therapies In the US, logistical and regulatory hurdles significantly limit home administration of oncology drugs, especially ...

With healthcare costs climbing, Stuart will lead the nonprofit insurer’s push to keep coverage affordable for 6 million ...

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...